| Literature DB >> 19447034 |
Kenji Naganuma1, Akifumi Omura, Naomi Maekawara, Masahiro Saitoh, Naoto Ohkawa, Takashi Kubota, Hiromitsu Nagumo, Toshiyuki Kodama, Masayoshi Takemura, Yuji Ohtsuka, Junji Nakamura, Ryuichi Tsujita, Koh Kawasaki, Hirotsugu Yokoi, Masashi Kawanishi.
Abstract
In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19447034 DOI： 10.1016/j.bmcl.2009.04.121
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823